Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Xu, Jingwei
LEONARDA-1, NCT05054751: GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer	Completed	3	275	RoW	GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant	Genor Biopharma Co., Ltd.	Locally Advanced or Metastatic Breast Cancer	12/22	03/24
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer	Active, not recruiting	3	274	RoW	BPI-16350, placebo, Fulvestrant	Betta Pharmaceuticals Co., Ltd.	Breast Cancer	12/23	07/25
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer	Active, not recruiting	3	866	Europe, Japan, US, RoW	Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219	Eli Lilly and Company, Eli Lilly and Company	Breast Neoplasms, Neoplasm Metastasis	06/24	08/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer	Recruiting	3	6000	Europe, Canada, Japan, US, RoW	Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane	Eli Lilly and Company	Breast Neoplasms	10/27	03/32
NCT05744687: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer	Recruiting	2/3	374	RoW	SPH4336 Tablets 400mg, SPH4336 Tablets Placebo	Shanghai Pharmaceuticals Holding Co., Ltd	Locally Advanced or Metastatic Breast Cancer	05/25	05/25
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer	Terminated	2	28	RoW	Mitoxantrone Hydrochloride Liposome Injection	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Breast Cancer	01/23	01/23